Sam Brusco, Associate Editor07.20.22
Heart failure (HF) treatment firm Endotronix will relocate and expand its Naperville, Ill. headquarters to support the upcoming U.S. launch of its Cordella HF system and pulmonary artery sensor, pending the U.S. Food and Drug Administration (FDA) premarket approval of the sensor.
The new building will allow for a 30% workforce expansion and increase Endotronix’s manufacturing and operating capacity. The facility will be 80,000+ square feet, more than doubling the company’s footprint. In addition to the U.S. office, the company will keep its Ireland office.
"This is an exciting time for Endotronix. As we approach full enrollment in our PROACTIVE-HF clinical trial, we are looking ahead toward scaling our manufacturing and operations in anticipation of commercialization of our proactive digital heart failure system," Harry Rowland, CEO of Endotronix told the press. "Naperville offers an ideal location to plant our roots, offering a skilled workforce, affordable quality of life for our employees, desirable proximity to Chicago, and strong sense of community."
Endotronix has been headquartered in Chicago area since 2013. The first phase of construction on the new facility aims to be completed in early 2023, with a hybrid workspace designed to accommodate a flexible workforce.
"It's a pleasure to welcome Endotronix to Naperville," said Steve Chirico, Mayor of Naperville. "As a fiscally-sound, business-friendly community that provides an unparalleled quality of life to its residents, we are a premier destination for growing companies like Endotronix. We look forward to being the home of their expanded commercial manufacturing and operations."
Endotronix released positive clinical data for the Cordella sensor from the European SIRONA 2 trial in May.
The new building will allow for a 30% workforce expansion and increase Endotronix’s manufacturing and operating capacity. The facility will be 80,000+ square feet, more than doubling the company’s footprint. In addition to the U.S. office, the company will keep its Ireland office.
"This is an exciting time for Endotronix. As we approach full enrollment in our PROACTIVE-HF clinical trial, we are looking ahead toward scaling our manufacturing and operations in anticipation of commercialization of our proactive digital heart failure system," Harry Rowland, CEO of Endotronix told the press. "Naperville offers an ideal location to plant our roots, offering a skilled workforce, affordable quality of life for our employees, desirable proximity to Chicago, and strong sense of community."
Endotronix has been headquartered in Chicago area since 2013. The first phase of construction on the new facility aims to be completed in early 2023, with a hybrid workspace designed to accommodate a flexible workforce.
"It's a pleasure to welcome Endotronix to Naperville," said Steve Chirico, Mayor of Naperville. "As a fiscally-sound, business-friendly community that provides an unparalleled quality of life to its residents, we are a premier destination for growing companies like Endotronix. We look forward to being the home of their expanded commercial manufacturing and operations."
Endotronix released positive clinical data for the Cordella sensor from the European SIRONA 2 trial in May.